



For UK Medical Media

First of its kind study to evaluate the effectiveness of combining established tolerable, generic medicines in the treatment of cancer

METRICS study investigates a new treatment route for patients for whom standard treatments are not viable or may benefit from adding this treatment

London, UK, 2nd September , 2014 – The Care Oncology Clinic, based in Harley Street, London announced today that it is recruiting patients onto a first-of-its-kind medical study to evaluate the effectiveness and tolerability of a unique combination of existing medicines in slowing the growth rate of tumours.

The open-label, observational METRICS study (Study of the Safety, Tolerability and Efficacy of Metabolic Treatments of Cancer), supported by The SEEK Group, aims to help patients who have been diagnosed with cancer and are unable to tolerate, see benefit from or have access to existing cancer therapies, or who may benefit from adding this treatment to the standard of care.

The METRICS study will examine the effect of tailored combinations of existing therapies, such as metformin, statins, doxycycline, mebendazole and ibuprofen, on the cancer cells' metabolism. METRICS will also assess the potential of this regimen to reduce tumour growth, with a primary outcome measure of progression-free survival over five years, alongside secondary quality of life and tumour response outcomes. METRICS builds on existing, published studies²⁻³¹ that demonstrate the potential of these metabolic therapies to inhibit tumour growth as monotherapy.

Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust, is leading the study and comments, “The METRICS study provides another option for those people for whom standard cancer treatment regimens are not viable, tolerable, available or providing any benefit on a stand-alone basis. The medicines prescribed in the study are well-established, having been used by a large number of people over a long period of time, with known side effects. The medicines have also been shown to reduce cancer growth rates. By studying these treatments in combination, it is hoped we will see a slowing of or retarding of cancer growth rates above and beyond using the medicines on their own at the same time as providing the patient with an improved quality of life”.



The METRICS study builds on existing evidence, evaluating the effectiveness of proven treatments in combination, rather than individually, to determine whether combination treatment will provide improved results at the same time as offering a better quality of life for study participants. Over time, data generated by the study will be collected and analysed, using standard study procedures, and subsequently published. It is hoped, in time, that the results from this study will establish this regime as a new, affordable treatment option.

“The SEEK Group is delighted to be able to support the Care Oncology Clinic in making this important study a reality. We have a strong heritage and interest in research and development of medicines and new treatment advances, which allows us to bring safe, effective and low cost medicines to patients in the shortest possible time to help improve patient outcomes and quality of life. We are excited to think that the outcomes of the study have the possibility to help dramatically improve the future standard of cancer care” Robin Bannister, CEO Strategy and Business Development, The SEEK Group.

If you would like to find out more or understand whether your patients could benefit from participation in the study, please visit www.careoncologyclinic.com or call +44 (0)207 580 3266.

- ENDS -

For further information, please contact:

Robin Bannister, SEEK Pharmaceuticals, +44 7980 254 128, robin.bannister@seekacure.com

Glenn Mursell, Packer Forbes, 020 7036 8550, glenn@packerforbes.com

Harriet Reynolds, Packer Forbes, 020 7036 8550, harriet@packerforbes.com

Notes to Editors

Cancer rates in the UK

There are around 330,000 new cases of cancer (excluding non-melanoma skin cancer) diagnosed each year in the UK, with more than 1 in 3 people likely to develop some form of cancer during their lifetime.³⁹

About the study

The study will evaluate the effectiveness and tolerability of combinations of established medicines, with differing metabolic impacts, for their potential to slow-down the growth and proliferation of cancer cells. The study is open to patients for whom no other treatments are available; patients who

can no longer be treated for reasons of cumulative toxicity; patients who are intolerant of current chemotherapy drugs; patients on round 3 or 4 of chemotherapy with low probability of success and patients who refuse traditional chemotherapy.

The Care Oncology Clinic use medicines which lower cholesterol, lower glucose, impact on glycolysis, mitochondria and apoptosis (cell death). A range of well-established options is available in each of these categories. Examples of the medicines used include:

- Metformin²⁻¹¹
- Statins¹²⁻¹⁶
- Doxycycline¹⁷⁻²¹
- Mebendazole²²⁻²⁸
- Ibuprofen²⁹⁻³¹

The study, launched in August 2014, already has a small number of patients enrolled and has recently been accepted by a number of NHS hospitals. The Care Oncology Clinic will continue to recruit patients into the study through each site and through patients directly with the support of their healthcare professional, until the target study number of 2,000 to 5,000 patients is reached. In the UK it is estimated that there are 500,000 existing patients who fit the study criteria with a further 150,000 eligible patients' being diagnosed each year.

When studies are conducted on existing medicines the sponsoring company, in this case The SEEK Group, does not benefit from commercial protection. Therefore, patients are asked to contribute towards the cost of their consultation and treatment while on the study.

About the Care Oncology Clinic

The Care Oncology Clinic, Harley Street is an independent, private healthcare provider for the treatment of cancer. Through its leading oncology consultants, the Care Oncology Clinic is currently undertaking a study of medical treatments, which aims to provide an acceptable quality of life, while showing significant, positive results in fighting the disease.

Care Oncology Clinic oncology consultants:

- Professor Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust,
- Professor Angus Dalglish, Foundation Chair of oncology at St George's, University of London



- *Dr David Feuer*, Senior Registrar & Research Fellow at The Royal Marsden NHS Trust and St Bartholomews

About SEEK Pharmaceuticals

Founded in 2004, the SEEK Group, headquartered in London, is involved in research and development of over the counter and prescription medicines and management and operation of clinics. It undertakes all these activities in order to bring safe, effective and low cost medicines to patients in the shortest possible time to radically improve human health in major disease areas.

The SEEK group together with other investors are providing financial backing to the Care Oncology Clinic to facilitate the running of the study. As the medicines involved are existing, generic therapies, The SEEK Group does not hold any commercial interest in the medicines and is acting on its ethos of bringing safe, effective and low costs medicines to patients in the shortest time possible to radically improve human health in cancer www.seekacure.com.

References

1. ClinicalTrials.Gov. NCT02201381. Study of the Safety, Tolerability and Efficacy of Metabolic Treatments of Cancer (METRICS).
<https://clinicaltrials.gov/ct2/show/NCT02201381?term=metrics&rank=6> Last accessed 27.08.14
2. Gallagher. E and LeRoith. D (2011) Diabetes, cancer, and metformin: connections of metabolism and cell proliferation, *Annals of the New York Academy and Sciences*, pp 64-68.
3. Yin. M, Zhou. J, Gorak. E and Quddus. F (2013) A Systematic Review and Meta-Analysis Metformin Is Associated With Survival Benefit in Cancer Patients with Concurrent Type 2 Diabetes, *The Oncologist*, 18(11).
4. Dowling RJO, et al. Understanding the benefit of metformin use in cancer treatment. *BMC Medicine* 2011, 9:33.
5. Martin-Castillio B, et al. Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. *Cell Cycle* 9:6, 1057-1064; March 15, 2010.
6. Cazzaniga M, et al. Is it Time to Test Metformin in Breast Cancer Clinical Trials? *Cancer Epidemiol Biomarkers Prev* 2009;18:701-705.
7. DeSensi A, et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. *Cancer Prev Res* 2010;3:1451-1461.
8. Landman GWD, et al. Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes. *Diabetes Care*, Volume 33, Number 2, February 2010
9. Ioannou GN, Boyko EJ. Metformin and Colorectal Cancer Risk in Diabetic Patients. *Diabetes Care*, Volume 34, October 2011.
10. Ben Sahra I, et al. Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? *Mol Cancer Ther* 2010;9:1092-1099.
11. Gallagher. J (2013) Cholesterol fuels breast cancer [online]
<http://www.bbc.co.uk/news/health-25142026> [accessed 2/12/13].
12. Singh. S and Singh. P (2013) Statin a day keeps cancer at bay, *World Journal of Clinical Oncology*, 4(2), 43-46.
13. Hindler. K, Cleeland. C, Rivera. E and Collard. C (2006) The Role of Statins in Cancer Therapy, *The Oncologist*, (11) 306–315.
14. Nielsen SF, et al. Statin Use and Reduced Cancer-Related Mortality. *N Engl J Med* 2012;367:1792-802.
15. Bansal D, et al. Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. *PLoS ONE* 7(10):e46691. doi:10.1371/journal.pone.0046691
16. Sherri R. Davies, Ada A. Cole and Thomas M. Schmid (1996), Doxycycline Inhibits Type X Collagen Synthesis in Avian Hypertrophic Chondrocyte Cultures, *The Journal of Biological Chemistry*, (271)25966-25970.
17. Onoda T, et al. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. *Int. J. Cancer*: 118, 1309–1315 (2006).
18. Duivenvoorden WCM, et al. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. *British Journal of Cancer* (2007) 96, 1526 – 1531
19. Duivenvoorden WCM, et al. Doxycycline Decreases Tumor Burden in a Bone Metastasis Model of Human Breast Cancer. *Cancer Res* 2002;62:1588-1591.
20. Fife RS, Sledge GW Jr. Effects of doxycycline on cancer cells in vitro and in vivo. *Adv Dent Res* 12:94-96, November, 1998
21. Nygren P, et al. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. *J Cancer Res Clin Oncol* (2013) 139:2133–2140
22. Dobrosotskaya IY, et al. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. *Endocrine Practice* Vol 17 No 3 May/June 2011 e59

23. Mukhopadhyay T, et al. Mebendazole Elicits a Potent Antitumor Effect on Human Cancer Cell Lines Both in Vitro and in Vivo. *Clin Cancer Res* 2002;8:2963-2969.
24. Pantziarka P, et al. Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. *ecancer* 2014, 8:443
25. Doudican N, et al. Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells. *Mol Cancer Res* 2008;6:1308-1315.
26. Sasaki J, et al. The Anthelmintic Drug Mebendazole Induces Mitotic Arrest and Apoptosis by Depolymerizing Tubulin in Non-Small Cell Lung Cancer Cells. *Mol Cancer Ther* 2002;1:1201-1209.
27. Bai RY, et al. Antiparasitic Mebendazole Shows Survival Benefit in 2 Preclinical Models of Glioblastoma Multiforme. *Neuro-Oncology*. doi:10.1093/neuonc/nor077
28. Harris. R, Beebe-Donk. J, Doss. H and Doss. D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review) *Oncology Reports*, 13(4), pp 559 – 583.
29. Wigmore SJ, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. *British Journal of Cancer* (1995) 72 185-188
30. Harris, R., Beebe-Donk, J., Doss, H., & Doss, D. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review). *Oncology Reports*, 13(4), 559-583.
31. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer Therapeutics. *Cell Death and Disease* (2013) 4, e532; doi:10.1038/cddis.2013.60
32. Hsu PP, Sabatini DM. Cancer Cell Metabolism: Warburg and Beyond. *Cell* 134, September 5, 2008. DOI 10.1016/j.cell.2008.08.021
33. Dolfi SC, et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. *Cancer & Metabolism* 2013, 1:20
34. Vazquez et al. Catabolic efficiency of aerobic glycolysis: The Warburg effect revisited. *BMC Systems Biology* 2010, 4:58
35. Kroemer G, et al. Tumor Cell Metabolism: Cancer's Achilles' Heel. *Cancer Cell* 13, June 2008. 472-482
36. Muñoz-Pinedo C, et al. Cancer metabolism: current perspectives and future directions. *Cell Death and Disease* (2012) 3, e248; doi:10.1038/cddis.2011.123
37. Moreno-Sánchez R, et al. Energy metabolism in tumor cells. *FEBS Journal* 274 (2007) 1393–1418.
38. Cancer Research Campaign. Cancer Statistics. Key facts. All cancers combined. May 2014. http://publications.cancerresearchuk.org/downloads/Product/CS_KF_ALLCANCERS.pdf
Last accessed 20.8.14.